Towa Pharmaceutical Co., Ltd. (TYO:4553)
Japan flag Japan · Delayed Price · Currency is JPY
3,885.00
+10.00 (0.26%)
Aug 25, 2026, 3:30 PM JST

Towa Pharmaceutical Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
8,26813,16526,33024,4594,60522,246
Depreciation & Amortization
22,65022,83720,09917,88819,40910,954
Loss (Gain) From Sale of Assets
11414,837-218-225478-96
Loss (Gain) From Sale of Investments
-24-243-18195
Other Operating Activities
-5,351-8,267-10,046-1,036-5,910-4,437
Change in Accounts Receivable
-4,405-792-565-15,523-1,592441
Change in Inventory
-14,000-13,790-7,204-6,288-18,496-7,950
Change in Accounts Payable
3,4692,9523,687-10,5096,5543,675
Change in Other Net Operating Assets
-184-489-8,685-536-2,523-2,709
Operating Cash Flow
25,26630,42923,4018,2122,54422,129
Operating Cash Flow Growth
-28.19%30.03%184.96%222.80%-88.50%84.28%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-20,982-22,277-28,736-37,851-28,731-11,140
Sale of Property, Plant & Equipment
13139123942
Cash Acquisitions
----1,570--45,405
Sale (Purchase) of Intangibles
-1,921-1,851-2,211-1,055-1,723-2,353
Investment in Securities
-1,492-1,492-203-50-26717
Other Investing Activities
137-53-146131198-220
Investing Cash Flow
-24,245-25,660-31,287-40,394-30,284-59,729

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-2,0811,603--47,135
Long-Term Debt Issued
-10,89826,36546,93578,8319,160
Total Debt Issued
14,89112,97927,96846,93578,83156,295
Short-Term Debt Repaid
----768-45,680-
Long-Term Debt Repaid
--19,409-12,592-7,607-12,268-7,181
Total Debt Repaid
-24,401-19,409-12,592-8,375-57,948-7,181
Net Debt Issued (Repaid)
-9,510-6,43015,37638,56020,88349,114
Issuance of Common Stock
-----21
Common Dividends Paid
-3,946-3,937-2,953-2,952-3,100-2,411
Other Financing Activities
293,5399,144-201-302-184
Financing Cash Flow
-13,427-6,82821,56735,40717,48146,540

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
1,1941,4101,9162,1671,685975
Miscellaneous Cash Flow Adjustments
-2121211-
Net Cash Flow
-11,214-64815,8095,393-8,5739,915

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
4,2848,152-5,335-29,639-26,18710,989
Free Cash Flow Growth
29.39%----282.76%
Free Cash Flow Margin
1.53%2.98%-2.05%-13.00%-12.54%6.64%
Free Cash Flow Per Share
87.02165.60-108.38-602.17-532.02218.36
Levered Free Cash Flow
--2,864-15,700-32,622-27,055-1,466
Unlevered Free Cash Flow
--1,451-14,683-32,030-26,658-1,322

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
2,3092,2291,594941610226
Cash Income Tax Paid
8,3258,52210,8891,7606,2854,748
Change in Working Capital
-15,120-12,119-12,767-32,856-16,057-6,543